Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a biopharmaceutical company developing and manufacturing innovative monoclonal antibodies for the treatment of cancer and serious viral infections.
Upcoming events:
| Sep 5–6, 2012 | Stifel Nicolaus Healthcare Conference 2012
|
Sep 7, 2012
1:40 PM CT | 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
|
| Session: | PLEN-Plenary Session | | Friday, Sep 07, 2012, 12:30 PM - 2:30 PM | | Presentation: | LBPL2 - Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer (Top-line Results) | | Pres. Time: | Friday, Sep 07, 2012, 1:40 PM - 1:50 PM | | Category: | Locally Advanced Non-small Cell Lung Cancer | | Keywords: | bavituximab; docetaxel; non-small-cell lung cancer | | Author(s): | D. E. Gerber1, M. Joppert2, D. R. Spigel3, D. P. Singh4, D. Giorgadze5, M. Shtivelband6, O. V. Ponomarova7, J. Shan8, C. P. Belani9, 1Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 2Florida Cancer Specialists, Ft. Meyers, FL, 3Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, 4Department of Radiotherapy & Clinical Oncology, S.M.S. Medical College & Attached Hospitals, Jaipur, India, 5Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia, 6Ironwood Cancer and Research Centers, Chandler, AZ, 7RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kiev, Ukraine, 8Peregrine Pharmaceuticals, Inc., Tustin, CA, 9Penn State Hershey Cancer Institute, Hershey, PA | | Disclosures: | D.E. Gerber: E. Research Grant; Peregrine Pharmaceuticals, Inc.. M. Joppert: None. D.R. Spigel: None. D.P. Singh: None. D. Giorgadze: None. M. Shtivelband: None. O.V. Ponomarova: None. J. Shan: K. Stock; Peregrine Pharmaceuticals, Inc.. Q. Leadership; Peregrine Pharmaceuticals, Inc.. C.P. Belani: None.
| Sep 20–21, 2012
| | Credit Suisse 3rd Annual Small & Mid Cap Conference
| | Sep 28–Oct 2, 2012 | 2012 European Society for Medical Oncology (ESMO) Annual Congress |
Late-Breaking Poster Discussion
Randomized, Double-Blind, Placebo Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer....................................................................................................................................................................... 
.........................................................................................................................................................................
Dedicated to Delivering Scientific Research & Clinical Results The world's most respected protein engineering and science meeting just got even better! Now in its 23rd year, this true scientific program covers the full spectrum of challenges in this space from basic science through clinical development.
"Antibody Engineering is a comprehensive conference covering the critical topics in the fields of antibody engineering and therapy." - Greg Adams, Co-Leader, Development Therapeutics Program, Fox Chase Cancer Center
Proven Clinical Results
University of Texas Southwestern examines clinical studies of Bavituximab used to overcome immune suppression in tumors
ibclifesciences.com
A new national initiative involving where volunteers can be matched to a scientific research project, or clinical trial, for which they might qualify.
Interested adult volunteers, parents or caregivers register on the ResearchMatch Web site (www.researchmatch.org) and indicate their interest in participating in research studies. Both healthy volunteers and those with specific medical conditions can sign up.
Message 26090452
CRISP has a new site for checking on grants.
projectreporter.nih.gov
Government link for definions used in trials.
prsinfo.clinicaltrials.gov
Patent office definitions:
uspto.gov |
